Patents

TICEBA is the only company worldwide disposing of the exclusive license of the patent from Brigham and Women's Hospital, university hospital of the Harvard Medical School in Boston/USA, entitling them to determine and isolate the valuable ABCB5+ stem cells.

TICEBA is exclusive licensee of the following patents:

USA

  • Frank MH and Sayegh MH; The Brigham and Women’s Hospital, Inc. "Gene encoding a multidrug resistance human P-glycoprotein homologue on chromosome 7p15-21 and uses thereof." US Patent 6,846,883. January 25, 2005.
  • Frank MH and Sayegh MH; The Brigham and Women’s Hospital, Inc. "Gene encoding a multidrug resistance human P-glycoprotein homologue on chromosome 7p15-2 and uses thereof." US Patent 7,465,554. December 16, 2008.
  • Frank MH and Sayegh MH; The Brigham and Women’s Hospital, Inc. "Gene encoding a multidrug resistance human P-glycoprotein homologue on chromosome 7p15-21 and uses thereof." US Patent 8,076,091. December 13, 2011.
  • Frank MH; The Brigham and Women’s Hospital, Inc. "ABCB5 positive mesenchymal stem cells as immunmodulators." US Patent 8,455,245. June 4, 2013.

Europe

  • Frank MH and Sayegh MH; The Brigham and Women’s Hospital, Inc. "A gene encoding a multidrug resistance human P-glycoprotein homologue on chromosome 7p15-21 and uses thereof." European Patent EP1290028. 01. December 2010.
News
Coronavirus and Mesenchymal Stem Cells

Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus

Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19)

Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus

Article about our study with limbal stem cells

On the website of the Harvard Stem Cell Institute you will find the following news release about the ongoing clinical trial conducted by our daughter company RHEACELL in patients suffering from limbal stem cell deficiency: Restoring vision: A stem cell therapy for cornea regeneration reaches the clinical-trial stage.

Clinical Trial - EB

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and several European competent national regulatory authorities. The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) for the treatment of EB.

Clinical Trial - LSCD

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and the German regulatory authority (Paul Ehrlich Institute). The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) and Fast Track designation from the FDA for the treatment of LSCD.

Safety

In a comprehensive preclinical study program, safety and local tolerability of ABCB5+ MSCs following subcutaneous, intramuscular and intravenous application has been demonstrated (Tappenbeck et al., 2019).

Newsletter